AI-Guided Screening for Cardiac Amyloidosis (EchoNet-Screening)
This study, called EchoNet-Screening, is looking at a new way to find a rare heart condition called cardiac amyloidosis. Researchers are using an artificial intelligence (AI) tool, called EchoNet-LVH, to analyze echocardiograms (heart ultrasounds). This AI tool helps identify signs of cardiac amyloidosis, like a thickened heart muscle (LVH). If the AI tool suggests a high chance of cardiac amyloidosis, you would be referred to a special clinic for more tests and care. The main goal is to see how many new cases of cardiac amyloidosis are found using this AI screening method over six months. You could join if the AI algorithm suggests you have a high suspicion for cardiac amyloidosis and you are at least 18 years old.
- Study design
- This is an observational study that plans to include 300 participants. It is not specified if participants are randomly assigned to groups or if the study is blinded.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcome is measured at 6 months, suggesting a follow-up period of at least that long.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases (EchoNet-Screening)
At a glance
Conditions
NCT05139797
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Cedars-Sinai Medical Centre (Los Angeles)
Los Angeles, Californiastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Number of New Diagnoses of Cardiac Amyloidosis Found6 months
From chart review, identification of patients who have a downstream diagnosis of cardiac amyloidosis